LAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Standard BioTools Inc (LAB) is not a strong buy at this time for a beginner investor with a long-term strategy. The technical indicators are mixed, the financial performance is weak, and there are no significant positive catalysts or trading signals. While the options data shows a bullish sentiment, the lack of strong growth trends and poor financials make this stock unsuitable for long-term investment at the moment.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 40.735, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 0.966, with key support at 0.933 and resistance at 0.998. Overall, the technical indicators suggest mixed signals.
The stock has a 100% chance of increasing by 2.23% in the next day, 7.71% in the next week, and 25.22% in the next month based on historical candlestick patterns. The MACD is also showing positive momentum.
No recent news or significant trading trends from hedge funds or insiders. Financial performance is weak, with a significant drop in net income (-156.59% YoY) and EPS (-155.56% YoY). Gross margin also declined by 3.02% YoY.
In Q4 2025, revenue remained flat YoY at $23.795 million. However, net income dropped significantly to -$19.283 million (-156.59% YoY), and EPS fell to 0.05 (-155.56% YoY). Gross margin decreased slightly to 47.83% (-3.02% YoY), indicating weak financial health.
No analyst ratings or price target changes were provided for this stock.
